blocking. Use Caution/Monitor.istradefyllineMonitor Closely (1)istradefylline will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.itraconazoleContraindicated (2)itraconazole increases levels of alfuzosin by decreasing metabolism. Contraindicated. alfuzosin and itraconazole both increase QTc interval. Contraindicated.ivosidenibSerious - Use Alternative (2)ivosidenib and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation. ivosidenib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.ketoconazoleContraindicated (1)ketoconazole increases levels of alfuzosin by decreasing metabolism. Contraindicated.Monitor Closely (1)ketoconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ketoprofenMonitor Closely (1)ketoprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ketorolacMonitor Closely (1)ketorolac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ketorolac intranasalMonitor Closely (1)ketorolac intranasal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.labetalolMonitor Closely (1)alfuzosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.lapatinibMonitor Closely (2)lapatinib and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and lapatinib both increase QTc interval. Use Caution/Monitor.Minor (1)lapatinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.larotrectinibMinor (1)larotrectinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.lefamulinContraindicated (1)lefamulin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval.lenacapavirMonitor Closely (1)lenacapavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.lenvatinibMonitor Closely (1)alfuzosin and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.letermovirMonitor Closely (1)letermovir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.leuprolideMonitor Closely (1)leuprolide and alfuzosin both increase QTc interval. Use Caution/Monitor. Increases risk of torsades de pointeslevalbuterolMonitor Closely (1)alfuzosin and levalbuterol both increase QTc interval. Use Caution/Monitor.levofloxacinMonitor Closely (2)levofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and levofloxacin both increase QTc interval. Use Caution/Monitor.levoketoconazoleContraindicated (1)levoketoconazole increases levels of alfuzosin by decreasing metabolism. Contraindicated.Monitor Closely (1)levoketoconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lisinoprilMonitor Closely (1)lisinopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.lithiumMonitor Closely (1)alfuzosin and lithium both increase QTc interval. Use Caution/Monitor.lofexidineMonitor Closely (1)lofexidine and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and lofexidine both increase QTc interval. Avoid or Use Alternate Drug.lonafarnibSerious - Use Alternative (1)lonafarnib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.loperamideMonitor Closely (1)alfuzosin and loperamide both increase QTc interval. Use Caution/Monitor.lopinavirContraindicated (1)lopinavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (1)lopinavir and alfuzosin both increase QTc interval. Use Caution/Monitor.lorlatinibMonitor Closely (1)lorlatinib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lornoxicamMonitor Closely (1)lornoxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.lumefantrineMonitor Closely (1)lumefantrine and alfuzosin both increase QTc interval. Use Caution/Monitor.Minor (1)lumefantrine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.lurasidoneMonitor Closely (1)lurasidone increases effects of alfuzosin by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.macimorelinSerious - Use Alternative (1)macimorelin and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.maprotilineMonitor Closely (2)maprotiline and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and maprotiline both increase QTc interval. Use Caution/Monitor.maravirocMonitor Closely (1)maraviroc, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.marijuanaMinor (1)marijuana will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.meclofenamateMonitor Closely (1)meclofenamate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.mefenamic acidMonitor Closely (1)mefenamic acid decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.mefloquineMonitor Closely (2)mefloquine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and mefloquine both increase QTc interval. Use Caution/Monitor.meloxicamMonitor Closely (1)meloxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.methadoneMonitor Closely (1)methadone and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and methadone both increase QTc interval. Avoid or Use Alternate Drug.methylprednisoloneMinor (1)methylprednisolone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.metoprololMonitor Closely (1)alfuzosin and metoprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.metronidazoleMinor (1)metronidazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.miconazole vaginalMinor (1)miconazole vaginal will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.midostaurinSerious - Use Alternative (1)alfuzosin and midostaurin both increase QTc interval. Avoid or Use Alternate Drug.mifepristoneContraindicated (1)mifepristone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Serious - Use Alternative (2)alfuzosin and mifepristone both increase QTc interval. Contraindicated. mifepristone and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Use alternatives if availablemirtazapineMonitor Closely (1)alfuzosin and mirtazapine both increase QTc interval. Use Caution/Monitor.mitotaneMonitor Closely (1)mitotane decreases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.mobocertinibSerious - Use Alternative (1)mobocertinib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequentlymoexiprilMonitor Closely (1)moexipril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.moxifloxacinMonitor Closely (1)moxifloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.moxisylyteMonitor Closely (1)alfuzosin and moxisylyte both increase anti-hypertensive channel blocking. Use Caution/Monitor.nabumetoneMonitor Closely (1)nabumetone decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.nadololMonitor Closely (1)alfuzosin and nadolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.naproxenMonitor Closely (1)naproxen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.nebivololMonitor Closely (1)alfuzosin and nebivolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.nefazodoneContraindicated (1)nefazodone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.nelfinavirContraindicated (1)nelfinavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.nevirapineMonitor Closely (1)nevirapine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nicardipineMonitor Closely (1)alfuzosin and nicardipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nifedipineMonitor Closely (1)alfuzosin and nifedipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.Minor (1)nifedipine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.nilotinibMonitor Closely (1)nilotinib and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and nilotinib both decrease QTc interval. Avoid or Use Alternate Drug.Minor (1)nilotinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.nirmatrelvirContraindicated (1)nirmatrelvir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.nirmatrelvir/ritonavirContraindicated (1)nirmatrelvir/ritonavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.nisoldipineMonitor Closely (1)alfuzosin and nisoldipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nitroglycerin rectalMonitor Closely (1)nitroglycerin rectal, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .nortriptylineMonitor Closely (2)nortriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and nortriptyline both increase QTc interval. Use Caution/Monitor.octreotideMonitor Closely (2)octreotide and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and octreotide both increase QTc interval. Use Caution/Monitor.ofloxacinMonitor Closely (2)ofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and ofloxacin both increase QTc interval. Use Caution/Monitor.olanzapineMonitor Closely (2)olanzapine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesolodaterol inhaledMonitor Closely (1)alfuzosin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)Contraindicated (1)ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increased risk for hypotensioondansetronMonitor Closely (1)ondansetron and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.osilodrostatMonitor Closely (2)osilodrostat and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and osilodrostat both increase QTc interval. Use Caution/Monitor. Dose dependent QT prolongation - avoid drugs known to prolong the QT intervalosimertinibMonitor Closely (1)osimertinib and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and osimertinib both increase QTc interval. Avoid or Use Alternate Drug.oxaliplatinMonitor Closely (1)oxaliplatin will increase the level or effect of alfuzosin by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.Serious - Use Alternative (1)alfuzosin and oxaliplatin both increase QTc interval. Avoid or Use Alternate Drug.oxaprozinMonitor Closely (1)oxaprozin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.oxcarbazepineMinor (1)oxcarbazepine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.oxymetazoline topicalMonitor Closely (1)oxymetazoline topical increases and alfuzosin decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.ozanimodMonitor Closely (1)ozanimod and alfuzosin both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.paliperidoneMonitor Closely (1)paliperidone and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and paliperidone both increase QTc interval. Avoid or Use Alternate Drug.panobinostatMonitor Closely (1)panobinostat and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.parecoxibMonitor Closely (1)parecoxib decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.paroxetineMonitor Closely (1)paroxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.pasireotideMonitor Closely (2)pasireotide and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.pazopanibMonitor Closely (1)pazopanib and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and pazopanib both increase QTc interval. Avoid or Use Alternate Drug.penbutololMonitor Closely (1)alfuzosin and penbutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.pentamidineMonitor Closely (1)pentamidine and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and pentamidine both increase